Details

Autor(en) / Beteiligte

• Deipolyi, Amy R., MD, PhD
• Oklu, Rahmi, MD, PhD
• Al-Ansari, Shehab, MD
• Zhu, Andrew X., MD, PhD
• Goyal, Lipika, MD
• Ganguli, Suvranu, MD

Titel

Safety and Efficacy of 70–150 μm and 100–300 μm Drug-Eluting Bead Transarterial Chemoembolization for Hepatocellular Carcinoma

Ist Teil von

• Journal of vascular and interventional radiology, 2015-04, Vol.26 (4), p.516-522

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2015

Quelle

MEDLINE

Beschreibungen/Notizen

• Abstract Purpose To compare the safety and efficacy of using 70–150 μm drug-eluting beads (DEBs) (LC Bead M1 ; Biocompatibles UK Ltd, Farnham, Surrey, United Kingdom) in addition to 100–300 μm DEBs with 100–300 μm DEBs alone in transarterial chemoembolization for treatment of hepatocellular carcinoma (HCC). Materials and Methods A cohort of patients with HCC who underwent transarterial chemoembolization with two vials of 100–300 μm DEBs (group 1, 55 procedures among 42 patients, 33 men, average Model for End-Stage Liver Disease score 10 ± 0.6, 67% Child-Pugh A, 33% Child-Pugh B) was retrospectively compared with a cohort of patients who underwent transarterial chemoembolization with one vial of 70–150 μm DEBs followed by one vial of 100–300 μm DEBs (group 2, 51 procedures among 42 patients, 29 men, average Model for End-Stage Liver Disease score 9 ± 0.6, 73% Child-Pugh A, 27% Child-Pugh B) in regard to adverse events and response on 1-month follow-up imaging using modified Response Evaluation Criteria In Solid Tumors criteria. Results There was no difference in 1-month imaging response ( P = .3). Patients in group 2 were readmitted more often within 1 month for hepatobiliary adverse events (group 2, 25%; group 1, 9%; P < .0001), including ascites, gastrointestinal hemorrhage, biliary dilatation, and cholecystitis. Conclusions Despite similar efficacy based on short-term follow-up imaging, transarterial chemoembolization with smaller DEBs (70–150 μm) followed by larger DEBs (100–300 μm) may cause more hepatobiliary adverse events.